Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

57.54 -0.46 (-0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise. 
Via Benzinga
Topics Stocks
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Earnings Economy
Earnings Scheduled For August 4, 2025
 
Via Benzinga
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN): A Prime Value Investment with Strong Fundamentals and Growth Potential
Value investing highlights undervalued stocks like BioMarin Pharmaceutical, with strong financials, earnings, and growth potential, offering a margin of safety. 
Via Chartmill
BMRN Q2 Deep Dive: Pipeline Advances and Strategic Expansion Drive Upbeat Results
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year... 
Via StockStory
Is BioMarin Pharmaceutical Gaining or Losing Market Support?
 
Via Benzinga
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030
BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth. 
Via Benzinga
BioMarin (BMRN) Q2 Revenue Jumps 16%
Via The Motley Fool
Topics Economy
BioMarin (BMRN) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year... 
Via StockStory
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Exceeds Q2 2025 Earnings Expectations, Shares Climb After Hours
BioMarin Pharmaceutical beats Q2 2025 estimates with $825.4M revenue, EPS of $1.44, and raises full-year guidance. Stock surges 4.6% post-earnings. 
Via Chartmill
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings this Monday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
What's Next: Biomarin Pharmaceutical's Earnings Preview
 
Via Benzinga
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad patient impact. 
Via Benzinga
1 Mid-Cap Stock Worth Investigating and 2 We Turn Down
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
What Does the Market Think About BioMarin Pharmaceutical?
 
Via Benzinga
Demystifying BioMarin Pharmaceutical: Insights From 4 Analyst Reviews
 
Via Benzinga
1 Cash-Producing Stock to Consider Right Now and 2 We Ignore
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) shows strong profitability, solid financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector. 
Via Chartmill
Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money
Three magnificent businesses with well-defined catalysts can deliver triple-digit returns amid a historically pricey stock market. 
Via The Motley Fool
Topics Economy Stocks
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. 
Via StockStory
Topics Artificial Intelligence
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock With Strong Fundamentals
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
2 Profitable Stocks for Long-Term Investors and 1 to Be Wary Of
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
2 Reasons to Watch BMRN and 1 to Stay Cautious
Over the last six months, BioMarin Pharmaceutical’s shares have sunk to $55.23, producing a disappointing 16.7% loss while the S&P 500 was flat. This might have investors contemplating their next... 
Via StockStory
Topics Stocks
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said. 
Via Benzinga
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
A volatile stock market represents an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Stocks
1 Mid-Cap Stock with Exciting Potential and 2 to Avoid
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) appears undervalued with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
Top movers in Friday's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.